US Institute of Medicine proposes biomarker validation framework
This article was originally published in Clinica
The US FDA should adopt a three-step framework for evaluating and validating biomarkers and convene expert panels to scrutinise those biomarkers that have “regulatory impact”, a US Institute of Medicine (IoM) committee says.
You may also be interested in...
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.
Sponsor seeks accelerated approval for low-risk, early-stage prostate cancer based on a trial that met its coprimary endpoints, but agency says interpretation of those results is complicated by novelty of the outcomes, data quality issues and increase in genitourinary adverse events.
Unless reauthorized by Congress, the rare pediatric disease program will begin to expire in September; renewal could bring bigger changes across the three PRV programs, including an FDA-requested clarification of biologic products eligible for vouchers and reforms suggested by sponsors and other stakeholders in a recent GAO report.